AutoImmune Inc.
🏢 View company profile →32Patents
0Active
32Granted
34Portfolio score
Filing activity: Sep 25, 1992 → Dec 2, 1998
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5763396A | Method of treating or preventing type 1 diabetes by oral administration of insulin | Human Necessities | 125 | Expired |
| US5571499A | Treatment of autoimmune diseases by aerosol administration of autoantigens | Human Necessities | 82 | Expired |
| US5869093A | Treatment of immune diseases by oral administration of autoantigens | Human Necessities | 67 | Expired |
| US5571500A | Treatment of autoimmune diseases through administration by inhalation of autoantigens | Human Necessities | 65 | Expired |
| US5645820A | Treatment of autoimmune diseases by aerosol administration of autoantigens | Human Necessities | 64 | Expired |
| US5399347A | Method of treating rheumatoid arthritis with type II collagen | Human Necessities | 64 | Expired |
| US5641474A | Prevention of autoimmune diseases by aerosol administration of autoantigens | Human Necessities | 62 | Expired |
| US5869054A | Treatment of multiple sclerosis by oral administration of autoantigens | Human Necessities | 57 | Expired |
| US5641473A | Treatment of autoimmune diseases by aerosol administration of autoantigens | Human Necessities | 56 | Expired |
| US5733547A | Treatment of autoimmune arthritis by oral administration of type I or type III collagen | Human Necessities | 56 | Expired |
| US6703361B2 | Method of treating or preventing Type 1 diabetes by oral administration of insulin | Human Necessities | 54 | Expired |
| US5849298A | Treatment of multiple sclerosis by oral administration of bovine myelin | Human Necessities | 52 | Expired |
| US6645504B1 | Bystander suppression of type I diabetes by oral administration of glucagon | Human Necessities | 50 | Expired |
| US5858968A | Method of treating or preventing type 1 diabetes by oral administration of insulin | Human Necessities | 43 | Expired |
| US5858980A | Peptide fragments of myelin basic protein | Human Necessities | 42 | Expired |
| US6077509A | Peptide fragments of myelin basic protein | Human Necessities | 38 | Expired |
| US5840848A | Method for preparation of type II collagen | Human Necessities | 35 | Expired |
| US6036957A | Suppression of T-cell proliferation using peptide fragments of myelin basic protein | Human Necessities | 31 | Expired |
| US5643868A | Method of treating or preventing type 1 diabetes by oral administration of insulin | Human Necessities | 30 | Expired |
| US5593698A | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides | Human Necessities | 23 | Expired |
| US5843886A | Method of treating or preventing Type 1 diabetes by oral administration of insulin | Human Necessities | 16 | Expired |
| US5935577A | Treatment of autoimmune disease using tolerization in combination with methotrexate | Emerging Cross-Sectional Technologies | 14 | Expired |
| US5720955A | Method of treating rheumatoid arthritis with soluble collagen | Human Necessities | 12 | Expired |
| US5856446A | Method of treating rheumatoid arthritis with low dose type II collagen | Human Necessities | 11 | Expired |
| US5843445A | Method of treating rheumatoid arthritis with type II collagen | Human Necessities | 10 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.